• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增殖性肿瘤还是反应性过程?一例罕见的急性髓系白血病及治疗后短暂性巨核细胞增生伴JAK-2突变病例

Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.

作者信息

Wang Steven, Yan Jie, Zhou Guangde, Heintzelman Rebecca, Hou J Steve

机构信息

Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, 245 N. 15th Street, MS 435, Philadelphia, PA 19102, USA.

出版信息

Case Rep Hematol. 2016;2016:6054017. doi: 10.1155/2016/6054017. Epub 2016 Sep 26.

DOI:10.1155/2016/6054017
PMID:27752371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5056299/
Abstract

Myeloproliferative neoplasms (MPNs) are hematopoietic malignancies characterized by unchecked proliferation of differentiated myeloid cells. The most common BCR-ABL1-negative MPNs are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The discovery of JAK2 V617F mutation has improved our understanding of the molecular basis of MPN. The high frequency of JAK2 mutation in MPN makes JAK2 mutation testing an essential diagnostic tool and potential therapeutic target for MPN. Here, we present a rare case of a 34-year-old patient who was initially diagnosed with acute myeloid leukemia (AML) with mutated NPM1. After chemotherapy treatment followed by granulocyte colony stimulating factor administration, the patient achieved complete remission of AML. However, the bone marrow showed hypercellularity with granulocytic hyperplasia, markedly increased atypical megakaryocytes (50.2/HPF) with focal clustering, and reticulin fibrosis (3/4). JAK2 V617F mutation was also detected. Considering the possibility of AML transformed from a previous undiagnosed MPN, patient underwent peripheral blood allogenic stem cell transplant. This case illustrates the diagnostic challenges of firmly establishing a diagnosis between similar, but distinct, disease entities and an accurate clinicopathological differentiation is crucial.

摘要

骨髓增殖性肿瘤(MPN)是一种造血系统恶性肿瘤,其特征是分化的髓系细胞不受控制地增殖。最常见的BCR-ABL1阴性MPN是真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化。JAK2 V617F突变的发现增进了我们对MPN分子基础的理解。MPN中JAK2突变的高频率使得JAK2突变检测成为MPN的重要诊断工具和潜在治疗靶点。在此,我们报告一例罕见病例,一名34岁患者最初被诊断为伴有NPM1突变的急性髓系白血病(AML)。经过化疗并给予粒细胞集落刺激因子后,患者的AML达到完全缓解。然而,骨髓显示细胞增多,伴有粒细胞增生,非典型巨核细胞明显增多(50.2/HPF)且有局灶性聚集,以及网状纤维纤维化(3/4)。还检测到JAK2 V617F突变。考虑到AML可能由先前未诊断的MPN转化而来,患者接受了外周血异基因干细胞移植。该病例说明了在相似但不同的疾病实体之间准确建立诊断的诊断挑战,准确的临床病理鉴别至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/36bb059b94e0/CRIHEM2016-6054017.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/53e99e89a873/CRIHEM2016-6054017.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/2c8174f2e9d2/CRIHEM2016-6054017.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/36bb059b94e0/CRIHEM2016-6054017.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/53e99e89a873/CRIHEM2016-6054017.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/2c8174f2e9d2/CRIHEM2016-6054017.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72ba/5056299/36bb059b94e0/CRIHEM2016-6054017.003.jpg

相似文献

1
Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.骨髓增殖性肿瘤还是反应性过程?一例罕见的急性髓系白血病及治疗后短暂性巨核细胞增生伴JAK-2突变病例
Case Rep Hematol. 2016;2016:6054017. doi: 10.1155/2016/6054017. Epub 2016 Sep 26.
2
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.骨髓增殖性疾病诊断标准的概念变迁以及骨髓增殖性肿瘤的分子病因学与分类:从1950年的达梅谢克到2005年的万琴克尔及以后
Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.
3
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.骨髓增殖性疾病(原发性血小板增多症、真性红细胞增多症、原发性巨核细胞粒细胞化生及骨髓纤维化)的诊断、发病机制与治疗
Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0.
4
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.JAK2 V617F 阳性急性髓系白血病(AML):初发 AML 与由潜在骨髓增殖性肿瘤转化而来的继发性 AML 的比较。来自骨髓病理学组的一项研究。
Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16.
5
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
6
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.JAK2 V617F突变、自发性红细胞生成和巨核细胞生成、高敏血小板、活化白细胞以及内皮细胞在真性红细胞增多症和原发性血小板增多症血栓形成表现病因中的作用。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98. doi: 10.1055/s-2006-942759.
7
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.与骨髓增生性肿瘤向急性髓系白血病转化相关的 Janus 激酶 2 变异体。
Cancer. 2019 Jun 1;125(11):1855-1866. doi: 10.1002/cncr.31986. Epub 2019 Feb 27.
8
Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.三例骨髓增殖性肿瘤患者中同时存在BCR-ABL1易位和JAK2(V617F)突变
Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.
9
Protracted Clonal Trajectory of a V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia.急性髓系白血病长期缓解期出现的V617F阳性骨髓增殖性肿瘤的迁延性克隆轨迹
Case Rep Hematol. 2018 May 9;2018:8713020. doi: 10.1155/2018/8713020. eCollection 2018.
10
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.慢性髓性白血病中断点簇集区-阿贝尔森1重排与Janus激酶2 V617F突变共存:一例报告
World J Clin Cases. 2019 May 6;7(9):1087-1092. doi: 10.12998/wjcc.v7.i9.1087.

引用本文的文献

1
Janus Kinases in Leukemia.白血病中的Janus激酶
Cancers (Basel). 2021 Feb 14;13(4):800. doi: 10.3390/cancers13040800.
2
Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia.对急性髓系白血病诱导化疗后血小板增多症患者进行潜在骨髓增殖性肿瘤的筛查。
Leuk Res Rep. 2020 Aug 7;14:100218. doi: 10.1016/j.lrr.2020.100218. eCollection 2020.
3
Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.

本文引用的文献

1
A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.骨髓增殖性肿瘤白血病转化的危险因素、治疗及预后的简要更新
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S124-9. doi: 10.1016/j.clml.2016.02.016.
2
Ruxolitinib: A Review in Polycythaemia Vera.芦可替尼:真性红细胞增多症治疗药物。
Drugs. 2015 Oct;75(15):1773-81. doi: 10.1007/s40265-015-0470-2.
3
Molecular classification of myeloproliferative neoplasms-pros and cons.骨髓增殖性肿瘤的分子分类:利弊。
伴有JAK2 V617F突变的急性髓系白血病治疗期间发生的原发性血小板增多症:一篇符合CARE标准文章的病例报告
Medicine (Baltimore). 2018 Jul;97(27):e11331. doi: 10.1097/MD.0000000000011331.
Curr Hematol Malig Rep. 2013 Dec;8(4):342-50. doi: 10.1007/s11899-013-0179-9.
4
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.JAK2 p.V617F 检测及等位基因负荷在骨髓和外周血中的检测在骨髓增殖性肿瘤患者中的应用。
Blood. 2013 Nov 28;122(23):3784-6. doi: 10.1182/blood-2013-07-515676. Epub 2013 Sep 25.
5
Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.JAK2 抑制剂对骨髓增殖性肿瘤的敏感性和耐药性。
Int J Hematol. 2013 Jun;97(6):695-702. doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14.
6
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.分子通路:Jak/STAT 通路:突变、抑制剂和耐药性。
Clin Cancer Res. 2013 Apr 15;19(8):1933-40. doi: 10.1158/1078-0432.CCR-12-0284. Epub 2013 Feb 13.
7
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.急性髓系白血病中的基因突变与分子靶向治疗
Am J Blood Res. 2013;3(1):29-51. Epub 2013 Jan 17.
8
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.Janus 激酶 2(JAK2)在骨髓增殖性肿瘤中的作用:治疗意义。
Leuk Res. 2013 Apr;37(4):465-72. doi: 10.1016/j.leukres.2012.12.006. Epub 2013 Jan 11.
9
Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.骨髓增殖性肿瘤 2012:约翰·M·班尼特 80 岁生日演讲。
Leuk Res. 2012 Dec;36(12):1481-9. doi: 10.1016/j.leukres.2012.08.011. Epub 2012 Aug 21.
10
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.p-JAK2 的表达可预测临床结局,是急性髓系白血病的潜在分子靶点。
Int J Cancer. 2011 Nov 15;129(10):2512-21. doi: 10.1002/ijc.25910. Epub 2011 Apr 8.